EditorShayne C. Gad, BS (Whittier College, Chemistry and Biology, 1971) and PhD in Pharmacology/Toxicology (Texas, 1977), DABT, is the principal of Gad Consulting Services, a twenty-five-yearoldconsulting firm with nine employees and more than 500 clients (including 140 pharmaceuticalcompanies in the US and 50 overseas). Prior to this, he served in director-level and above positions atSearle, Synergen, and Beckton Dickinson. He has published 50 books and more than 350 chapters,articles, and abstracts in the fields of toxicology, statistics, pharmacology, drug development, andsafety assessment. He has more than 40 years of broad-based experience in toxicology, drug anddevice development, statistics, and risk assessment. He has specific expertise in neurotoxicology,in vitro methods, cardiovascular toxicology, inhalation toxicology, immunotoxicology, and genotoxicology.Past president of the American College of Toxicology, the Roundtable of ToxicologyConsultants, and three of SOT’s (Society of Toxicology) specialty sections. He has direct involvementin the preparation of Investigational New Drug applications (INDs, 115 successfully to date), NewDrug Application (NDA), Product License Application (PLA), Abbreviated New Drug Application(ANDA), 501(k), Investigational Device Exemption (IDE), Common Technical Document (CTD),clinical data bases for phase 1 and 2 studies, and Premarket Approval Applications (PMAs). He hasconsulted for the Food and Drug Administration (FDA), Environmental Protection Agency (EPA),and National Institutes of Health (NIH), has trained reviewers, and has been an expert witness forthe FDA. He has also conducted the triennial toxicology salary survey as a service to the professionfor the last 29 years.Dr. Gad is also a retired Navy officer with more than 26 years in service.
